David Tesarowski

3.1k total citations
14 papers, 343 citations indexed

About

David Tesarowski is a scholar working on Pulmonary and Respiratory Medicine, Equine and Animal Science and Zoology. According to data from OpenAlex, David Tesarowski has authored 14 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Equine and 4 papers in Animal Science and Zoology. Recurrent topics in David Tesarowski's work include Veterinary Equine Medical Research (5 papers), Breast Cancer Treatment Studies (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). David Tesarowski is often cited by papers focused on Veterinary Equine Medical Research (5 papers), Breast Cancer Treatment Studies (3 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers). David Tesarowski collaborates with scholars based in Canada, United States and Switzerland. David Tesarowski's co-authors include Laurent Viel, Simon Young, Wayne N. McDonell, Andrew M. Hoffman, Michael T. Newhouse, Dorothy M. Ainsworth, Frederick E. Hargreave, Kenneth R. Chapman, Mary Rose Paradis and Steven W. Eicker and has published in prestigious journals such as Cancer Research, Journal of Applied Physiology and CHEST Journal.

In The Last Decade

David Tesarowski

13 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Tesarowski Canada 10 160 120 89 72 63 14 343
T Shida Japan 9 54 0.3× 73 0.6× 21 0.2× 24 0.3× 24 0.4× 16 389
Jennifer Taintor United States 12 201 1.3× 73 0.6× 13 0.1× 31 0.4× 13 0.2× 30 370
Phillip F. Steyn United States 13 161 1.0× 113 0.9× 17 0.2× 12 0.2× 10 0.2× 29 467
Marc Henroteaux Belgium 12 18 0.1× 164 1.4× 43 0.5× 37 0.5× 35 0.6× 32 361
Bonnie Rush Moore United States 11 369 2.3× 43 0.4× 53 0.6× 51 0.7× 12 0.2× 14 510
Judy H. Cox United States 10 66 0.4× 44 0.4× 32 0.4× 31 0.4× 45 0.7× 15 253
Alessandro Pirrone Italy 10 140 0.9× 21 0.2× 17 0.2× 13 0.2× 8 0.1× 16 386
V. C. SPEIRS Australia 11 178 1.1× 46 0.4× 37 0.4× 25 0.3× 6 0.1× 18 270
J.R. Gibbons United States 14 40 0.3× 70 0.6× 16 0.2× 110 1.5× 7 0.1× 46 1.1k
Deanna M. W. Schaefer United States 10 49 0.3× 50 0.4× 12 0.1× 20 0.3× 48 0.8× 28 299

Countries citing papers authored by David Tesarowski

Since Specialization
Citations

This map shows the geographic impact of David Tesarowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tesarowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tesarowski more than expected).

Fields of papers citing papers by David Tesarowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tesarowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tesarowski. The network helps show where David Tesarowski may publish in the future.

Co-authorship network of co-authors of David Tesarowski

This figure shows the co-authorship network connecting the top 25 collaborators of David Tesarowski. A scholar is included among the top collaborators of David Tesarowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Tesarowski. David Tesarowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Loibl, Sibylle, Chiun‐Sheng Huang, Max S. Mano, et al.. (2022). Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. npj Breast Cancer. 8(1). 106–106. 22 indexed citations
2.
3.
Dhillon, Preet K., Vincent Antao, David Tesarowski, et al.. (2021). Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data. Cancer Research. 81(4_Supplement). PS10–20. 1 indexed citations
4.
5.
D’Urzo, Anthony, Kenneth R. Chapman, André Cartier, et al.. (2001). Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings. CHEST Journal. 119(3). 714–719. 35 indexed citations
6.
Viel, Laurent, Chander Celly, Henry R. Staempfli, & David Tesarowski. (1999). Therapeutic Efficacy of Inhaled Fluticasone Propionate in Horses with Chronic Obstructive Pulmonary Disease. 11 indexed citations
7.
Ainsworth, Dorothy M., Steven W. Eicker, Corinne R. Sweeney, et al.. (1998). Associations between physical examination, laboratory, and radiographic findings and outcome and subsequent racing performance of foals with Rhodococcus equi infection: 115 cases (1984-1992). Journal of the American Veterinary Medical Association. 213(4). 510–515. 73 indexed citations
8.
Young, Simon, David Tesarowski, & Laurent Viel. (1997). Frequency dependence of forced oscillatory respiratory mechanics in horses with heaves. Journal of Applied Physiology. 82(3). 983–987. 32 indexed citations
9.
Tesarowski, David, Laurent Viel, & Wayne N. McDonell. (1996). Pulmonary function measurements during repeated environmental challenge of horses with recurrent airway obstruction (heaves). American Journal of Veterinary Research. 57(8). 1214–1219. 62 indexed citations
10.
adams, jimi, et al.. (1996). 59 Pharmacoeconomic benefits of fluticasone propionate aqueous nasal spray 200μg once daily in perennial allergic rhinitis. Journal of Allergy and Clinical Immunology. 97(1). 197–197. 1 indexed citations
11.
Young, Simon & David Tesarowski. (1994). Respiratory mechanics of horses measured by conventional and forced oscillation techniques. Journal of Applied Physiology. 76(6). 2467–2472. 35 indexed citations
12.
Tesarowski, David, Laurent Viel, Wayne N. McDonell, & Michael T. Newhouse. (1994). The rapid and effective administration of a beta 2-agonist to horses with heaves using a compact inhalation device and metered-dose inhalers.. PubMed. 35(3). 170–3. 30 indexed citations
13.
Hoffman, Andrew M., Laurent Viel, David Tesarowski, & John D. Baird. (1993). Management of severe obstructive pulmonary disease with inhaled bronchodilator treatment in a horse.. PubMed. 34(8). 493–5. 13 indexed citations
14.
Whiting, Terry L & David Tesarowski. (1988). On the meaning and utility of diagnostic terms: Special reference to bronchopulmonary abnormalities in the horse.. PubMed. 29(10). 787–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Shida Breakdown of academic impact, for papers by Jennifer Taintor Breakdown of academic impact, for papers by Phillip F. Steyn Breakdown of academic impact, for papers by Marc Henroteaux Breakdown of academic impact, for papers by Bonnie Rush Moore Breakdown of academic impact, for papers by Judy H. Cox Breakdown of academic impact, for papers by Alessandro Pirrone Breakdown of academic impact, for papers by V. C. SPEIRS Breakdown of academic impact, for papers by J.R. Gibbons Breakdown of academic impact, for papers by Deanna M. W. Schaefer
Rankless by CCL
2026